8-K: Axsome Therapeutics' AXS-12 Achieves Primary Endpoint in Phase 3 Narcolepsy Trial

Axsome Therapeutics announced that AXS-12 met its primary endpoint in a Phase 3 trial, demonstrating a statistically significant reduction in cataplexy attacks compared to placebo in patients with narcolepsy.

Summary

• Axsome Therapeutics' AXS-12 (reboxetine) has successfully met the primary endpoint in the ENCORE Phase 3 trial for narcolepsy, showing a statistically significant reduction in the frequency of cataplexy attacks compared to placebo.
• The trial included a 6-month open-label treatment period followed by a 3-week double-blind, placebo-controlled withdrawal period.
• 68 patients were enrolled in the open-label phase, with 42 patients randomized in the double-blind phase to either continue AXS-12 or switch to placebo.
• Patients who switched to placebo experienced a significant increase of 10.29 cataplexy attacks per week compared to an increase of 1.32 attacks per week for those who continued on AXS-12.
• AXS-12 also demonstrated statistically significant improvements in cognition and overall narcolepsy symptoms compared to placebo.
• During the open-label phase, patients experienced a 71% reduction in cataplexy attacks at 1 month, which was sustained at 77% at 6 months.
• 72% of patients achieved a 50% reduction in cataplexy attacks at 1 month, increasing to 82% at 6 months.
• The percentage of cataplexy-free days increased from 14% at baseline to 61% at 1 month and 70% at 6 months.
• Excessive daytime sleepiness (EDS) improved, with mean ESS scores reduced by 5.6 points at 1 month and 7.3 points at 6 months.
• Cognition improved, with 55% of patients reporting improvement at 1 month and 59% at 6 months on the NSAQ, and 67% at 1 month and 70% at 6 months on the PGI-C.
• Overall narcolepsy status improved, with 90% of patients showing improvement at both 1 and 6 months on the CGI-C.
• Work impairment due to narcolepsy decreased from 53% at baseline to 24% at 6 months.
• The long-term safety profile of AXS-12 was consistent with previous trials, with no new safety signals detected.

Sentiment

Score: 9

Explanation: The document presents overwhelmingly positive results from a Phase 3 trial, with strong statistical significance and clear benefits for patients. The company's plan to move towards an NDA filing further boosts the positive sentiment.

Positives

• AXS-12 demonstrated a statistically significant reduction in cataplexy attacks compared to placebo.
• The drug showed statistically significant improvements in cognition and overall narcolepsy symptoms.
• A high percentage of patients achieved a 50% reduction in cataplexy attacks and improvements in EDS.
• The long-term safety profile of AXS-12 was consistent with previous trials.
• AXS-12 significantly increased the percentage of cataplexy-free days.
• The drug reduced work impairment due to narcolepsy.
• The results confirm the efficacy of AXS-12 in patients with narcolepsy with cataplexy, demonstrated in three positive controlled trials.
• The company plans to move expeditiously towards an NDA filing for AXS-12.

Negatives

• 17.6% of patients discontinued the trial due to adverse events during the 6-month open-label treatment period.
• The most common adverse events were nausea and tachycardia, each reported in 5.9% of patients.

Risks

• The company needs to successfully navigate the NDA filing process with the FDA.
• There is a risk that the FDA may not approve AXS-12 despite the positive trial results.
• The company needs to successfully commercialize AXS-12 if approved.
• There is a risk of unforeseen circumstances or disruptions to normal business operations.

Future Outlook

Axsome plans to move expeditiously towards an NDA filing for AXS-12 and intends to request a pre-NDA meeting with the FDA.

Management Comments

• Dr. Michael Thorpy commented that the results support AXS-12 as a potentially important new option for physicians and patients.
• Dr. Herriot Tabuteau, CEO of Axsome Therapeutics, stated that the results confirm the efficacy of AXS-12 and that the potential benefits are substantial and sustained with long-term treatment.
• Dr. Tabuteau also expressed pleasure with the improvements in cataplexy, excessive daytime sleepiness, and cognition.

Industry Context

This announcement is significant for the narcolepsy treatment landscape, as it provides further evidence for the efficacy of AXS-12, a novel treatment option. The positive results could position Axsome as a key player in the CNS therapeutics market.

Comparison to Industry Standards

• The results of the ENCORE trial are compared to previous trials of AXS-12, showing consistent efficacy and safety.
• The document references the need for new treatment options for narcolepsy, indicating that current treatments may not fully address the variety of disease presentations.
• The document does not directly compare AXS-12 to specific competitor products, but highlights the need for options that can address the variety in disease presentation, suggesting that AXS-12 may offer a unique approach.

Stakeholder Impact

• Shareholders are likely to react positively to the successful trial results.
• Patients with narcolepsy may benefit from a new treatment option.
• Physicians will have a new tool to manage narcolepsy symptoms.
• Employees of Axsome may experience increased job security and opportunities.

Next Steps

• Axsome plans to move expeditiously towards an NDA filing for AXS-12.
• The company intends to request a pre-NDA meeting with the FDA.

Key Dates

Keywords

AXS-12, narcolepsy, cataplexy, reboxetine, clinical trial, Phase 3, FDA, cognition, excessive daytime sleepiness, CNS disorders